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Objectives: Double valve replacement has been advocated for patients with com-
bined aortic and mitral valve disease. This study investigated the alternative that,
when feasible, mitral valve repair with aortic valve replacement is superior.
Patients and Methods: From 1975 to 1998, 813 patients underwent aortic valve
replacement with either mitral valve replacement (n 518) or mitral valve repair (n
 295). Mitral valve disease was rheumatic in 71% and degenerative in 20%. Mitral
valve replacement was more common in patients with severe mitral stenosis (P 
.0009), atrial fibrillation (P  .0006), and in patients receiving a mechanical aortic
prosthesis (P  .0002). These differences were used for propensity-matched mul-
tivariable comparisons. Follow-up extended reliably to 16 years, mean 6.9  5.9
years.
Results: Hospital mortality rate was 5.4% for mitral valve repair and 7.0% for
replacement (P  .4). Survivals at 5, 10, and 15 years were 79%, 63%, and 46%,
respectively, after mitral valve repair versus 72%, 52%, and 34%, respectively, after
replacement (P  .01). Late survival was increased by mitral valve repair rather
than replacement (P  .03) in all subsets of patients, including those with severe
mitral valve stenosis. After repair of nonrheumatic mitral valves, 5-, 10-, and
15-year freedom from valve replacement was 91%, 88%, and 86%, respectively; in
contrast, after repair of rheumatic valves, it was 97%, 89%, and 75% at these
intervals.
Conclusions: In patients with double valve disease, aortic valve replacement and
mitral valve repair (1) are feasible in many, (2) improve late survival rates, and (3)
are the preferred strategy when mitral valve repair is possible.
Ten percent of patients with valvular heart disease have involvementof both aortic and mitral valves.1-4 Most groups advocate doublevalve replacement for this entity.5,6 However, some data suggest asurvival advantage for the strategy of aortic valve replacementcombined with mitral valve repair.7,8 The benefits of mitral valverepair in patients with isolated mitral valve disease are well docu-
mented.9-11 The purposes of this study of patients with double valve disease were to
(1) identify features distinguishing patients having mitral valve repair versus re-
placement, (2) determine whether mitral valve repair confers a survival advantage
over valve replacement, (3) identify which patients benefit most from mitral valve
repair, and (4) assess the durability of the mitral valve repair.
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Patients and Methods
Study Group
From 1975 to 1998, 978 patients underwent simultaneous aortic
and mitral valve surgery at The Cleveland Clinic Foundation. Of
these, 813 underwent primary simultaneous aortic valve replace-
ment and either mitral valve replacement (n  518) or repair (n 
295) with or without concomitant tricuspid valve surgery or cor-
onary artery bypass grafting. They were identified as follows.
Initially, the Cardiovascular Information Registry (CVIR), whose
data has been approved for use in research, and the Institutional
Review Board were used to identify all patients having surgery for
combined aortic and mitral valve disease. Medical records were
then reviewed in detail to verify CVIR clinical data acquired
concurrently with patient care. Patients with double valve repair or
aortic valve repair and mitral valve replacement were excluded
from the study.12 Patients undergoing double valve procedures for
endocarditis were also excluded and are the subject of a separate
report.13
Definitions
Mitral valve disease was classified on the basis of analysis of
clinical information, operative reports, catheterization reports, and
echocardiograms. Degenerative mitral valve disease was consid-
ered to be present when the patient had mitral valve regurgitation
resulting from leaflet prolapse and pathologic findings at operation
consistent with degenerative disease.14 Rheumatic mitral valve
disease was considered to be present when the patient had mitral
valve stenosis or pathologic and echocardiographic findings con-
sistent with a rheumatic process.15 Patients were deemed to have
ischemic mitral valve regurgitation if they had papillary muscle
infarction or mitral valve regurgitation caused by changes in left
ventricular or anular geometry attributable to previous myocardial
infarction.16 Finally, patients with structurally normal mitral
valves and no history of myocardial infarction were considered to
have functional mitral valve regurgitation attributable to the effects
of aortic valve disease.
Patient Characteristics
Mean age of patients undergoing double valve replacement was 60
 13 years and among those receiving mitral valve repair was 61
 13 years (P  .16). Other patient characteristics, details of the
cause and pathophysiology of the valve disease, cardiac and non-
cardiac comorbidity, and the operative procedure are given in
Tables 1-3. Most patients had rheumatic valve disease and some
degree of mitral valve stenosis. Forty-three percent of patients
undergoing mitral valve repair had open mitral commissurotomy,
and 59% had an annuloplasty. Aortic prostheses included 301
mechanical valves and 512 bioprostheses. Mitral valve prostheses
included 202 mechanical valves and 317 bioprostheses. One pa-
tient had initial replacement with a mechanical prosthesis; a cal-
cified anulus caused a perivalvar leak, and the valve was replaced
with a bioprosthesis at the same operation. Operative reports did
not permit the determination of the extent to which chordal-sparing
techniques were used at mitral valve replacement. Concomitant
procedures included coronary artery bypass grafting in 237 pa-
tients (29%), including 100 with mitral valve repair (34%) and 137
with mitral valve replacement (26%). Sixty-two patients (8%) had
tricuspid valve repair.
Follow-up
Patients were monitored systematically at 2-year intervals by the
CVIR, with a mailed questionnaire, telephone interview, or exam-
ination at the Cleveland Clinic if within 6 months of the planned
follow-up. Thirty-eight patients had less than 6 months of follow-
up. Follow-up extended to 22 years, with 5163 patient-years of
information available for analysis. Mean follow-up among all
survivors was 6.9  5.9 years, with 50% followed up for more
than 4 years, 25% for more than 10 years, and 10% for more than
16 years. Patients undergoing aortic valve replacement and mitral
valve repair were followed up for a somewhat shorter period—
10% for more than 15.2 years and 7.4% for more than 16 years
(maximum 22 years)—whereas 10% of those undergoing mitral
valve replacement were followed up for more than 17.8 years
(maximum 22 years). On balance, then, we believe time-related
estimates were reliable to 16 years.
Data Analyses
Mitral valve replacement versus repair: Propensity
analysis. Repair or replacement of the mitral valve was by
surgeon choice. Therefore, attempts were made to adjust for se-
lection factors in the analyses. The probability that the patient’s
mitral valve would be replaced rather than repaired was estimated
by multivariable logistic regression by use of the demographic
information, clinical status, cause of valve disease, pathophysiol-
ogy of valve disease, and cardiac and noncardiac comorbidity
variables that are listed in Appendix Table 1. In addition, because
one of the possible selection criteria could have been whether the
patient would receive long-term anticoagulation, the variable “me-
chanical aortic prosthesis” was included in the analysis. Variable
selection for a parsimonious model was performed as described
below under Multivariable Analysis.
To the variables identified as being significant predictors of
mitral valve replacement, we added demographic, noncardiac mor-
bidity, cardiac comorbidity, and mitral valve etiology variables, no
matter their significance, to generate a propensity score for each
patient.17-19 The higher the score, the more likely it was that a
patient would undergo mitral valve replacement. This propensity
score was used to adjust the estimate of the effect of mitral valve
replacement versus repair in the multivariable analysis of outcome
for nonrandom selection factors.
Outcomes: Survival and durability of mitral valve
repair. Time-related outcomes were all-cause death and reopera-
tion. The analysis of reoperation focused primarily on mitral valve
replacement after mitral valve repair. Nonparametric estimates
used the Kaplan-Meier estimator. A parametric method was used
to resolve the number of phases of instantaneous risk (hazard
function) and to estimate their shaping parameters.20 (Available at
http://clevelandclinic.org/heartcenter/hazard.)
Multivariable analyses. Potential risk factors were organized
for entry into the various analyses as shown in Appendix Table 1.
Exploratory analysis of these variables included correlation anal-
ysis, multiple stratified life-table analyses compared by use of the
log-rank test, contingency table analyses, and simple t testing.
Continuous and ordinal variables were assessed univariably by
decile analysis to suggest transformations of scale to incorporate
into the multivariable analyses to ensure that the relationship of
these variables to outcome was well calibrated with respect to
model assumptions.
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For each of the hazard models, the multivariable analysis
simultaneously incorporated variables into each hazard phase. For
these, as well as the logistic regression analysis of propensity, a
directed technique of entry of variables was used.21 In all analyses
of outcome, both the propensity score and the variable indicating
mitral valve replacement rather than repair were always incorpo-
rated, regardless of their statistical significance. Additionally, in-
teraction terms were formed between all variables and the indica-
tion of mitral valve replacement rather than repair to investigate
the possibility that some variables had a differential influence in
one or the other group.
The P value criterion for retention of variables in the final
model was .1, except that both propensity score and the variable
indicating mitral valve replacement rather than repair were re-
tained in the analyses of outcome. This strategy does not, however,
balance against type I and type II statistical error. Therefore, we
supplemented the analyses with bootstrap random resampling,
repeated 1000 times, to determine the likelihood of variables
entering such an analysis at the 5% significance level.22,23
Analysis of benefit. To estimate the benefit of either mitral
valve replacement or repair, the multivariable survival equation
was solved for each patient twice, once as if the patient’s mitral
valve had been replaced and once again as if it had been repaired.
The difference in predicted percent survival at 16 years for each of
these two strategies was compared. The comparison included
multiple linear regression analysis of the survival differences for
their preoperative prediction as well as construction of stratified
cumulative distribution curves.
TABLE 1. Patient characteristics
Characteristic
Total
(n  813)
No. (%)
Mitral repair
(n  295)
No. (%)
Mitral replacement
(n  518)
No. (%) P value*
Demography
Age .2†
30 21 (3) 7 (2) 14 (3)
30-50 142 (17) 52 (18) 90 (17)
50-60 203 (25) 67 (23) 136 (26)
60-70 222 (27) 67 (23) 155 (30)
70 225 (28) 102 (34) 123 (24)
Male 419 (52) 160 (54) 259 (50) .2
Cardiac Comorbidity
NYHA functional class .7†
I 118 (15) 46 (16) 72 (14)
II 379 (47) 137 (46) 242 (47)
III 249 (31) 86 (29) 163 (31)
IV 67 (8) 26 (9) 41 (8)
Coronary artery disease‡ .01†
0-system disease (50%) 547 (68) 183 (63) 364 (72)
Single-system disease (50%) 116 (15) 48 (16) 68 (13)
Double-system disease (50%) 82 (10) 36 (12) 46 (9)
Triple-system disease (50%) 53 (7) 24 (8) 29 (6)
Atrial fibrillation 305 (38) 86 (29) 219 (42) .0002
Left main disease
Any 69 (9) 36 (12) 33 (6) .005
50% 29 (4) 14 (5) 15 (3) .2
LAD disease (50%) 155 (19) 68 (23) 87 (17) .03
LCx disease (50%) 128 (16) 54 (18) 74 (15) .1
RCA disease (50%) 156 (20) 70 (24) 86 (17) .02
Left ventricular dysfunction‡ .1
None 432 (54) 154 (53) 278 (55)
Mild 135 (17) 41 (14) 94 (18)
Moderate 168 (21) 66 (23) 102 (20)
Severe 63 (8) 30 (10) 33 (6)
Noncardiac comorbidity
COPD 65 (8) 29 (10) 36 (7) .14
Diabetes (oral- or insulin-treated) 71 (10) 34 (13) 37 (8) .03
Peripheral vascular disease 102 (12) 45 (15) 57 (11) .08
COPD, Chronic obstructive pulmonary disease; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; RCA, right coronary
artery.
*P is 2 or Fisher’s exact test as appropriate or, in the case of continuous or ordinal variables, a logistic test for trend.
†Logistic.
‡Information available for 291 mitral valve repair and 507 patients undergoing mitral valve replacement who underwent coronary angiography and left
ventriculography.
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Presentation. Mortality and survival estimates are accompa-
nied by asymmetric 68% confidence limits (CL), comparable to
1 standard error.
Results
Mitral Valve Replacement Versus Repair: Propensity
Analysis
Patients were more likely to undergo mitral valve replace-
ment if they had preoperative atrial fibrillation, severe mitral
valve stenosis, calcified mitral leaflets, or if a mechanical
aortic prosthesis was placed; mitral valve repair was more
likely if there were morphologically normal valve leaflets
with functional mitral valve regurgitation (Table 4). Earlier
in the experience, valve replacement was more common
(Appendix Figure 1, A).
Trends across the experience in the management of pa-
tients with double valve disease were identified (Appendix
Figure 1). In addition to a greater number of patients un-
dergoing mitral valve repair in later years, an increasing
number of patients came to operation for degenerative mi-
tral disease (P  .0001, Appendix Figure 1, B). In recent
years, fewer patients had atrial fibrillation (P  .0002) and
more patients underwent coronary artery revascularization
(P  .0001).
Survival Advantage of Mitral Valve Repair
Thirty-six (7.0%, CL 5.8% to 8.3%) patients died in the
hospital after undergoing double valve replacement and 16
patients (5.4%, CL 4.1% to 7.1%) after aortic valve replace-
ment and mitral valve repair (P  .4). The most common
modes of death were heart failure (34 patients, 65%) and
multiple organ dysfunction syndrome (10 patients, 19%).
TABLE 3. Mitral valve repair techniques (n  295)
Technique n %
Annuloplasty 173 59
Carpentier-Edwards 58 20
Cosgrove 63 21
Bovine pericardial 53 18
None 121 41
Commissurotomy 127 43
Leaflet resection 27 9
Chordal transfer 15 5
Chordal shortening 10 3
TABLE 2. Valve etiology and pathophysiology
Total
(n  813)
No. (%)
Repair
(n  295)
No. (%)
Replacement
(n  518)
No. (%) P value*
Mitral valve
Etiology†
Rheumatic 580 (71) 169 (57) 411 (79) .0001*
Degenerative 163 (20) 63 (21) 100 (19) .5
Functional 59 (7) 53 (18) 6 (1) .0001
Ischemic 8 (1) 7 (2) 1 (0.2) .004‡
Pathology
Anular calcification 161 (20) 65 (22) 96 (18) .2
Leaflet calcification 315 (39) 76 (26) 239 (46) .0001
Chordal rupture 44 (5) 23 (8) 21 (4) .02
Dilated anulus 98 (12) 83 (28) 15 (3) .0001
Pathophysiology§
Regurgitation 156 (19) 58 (20) 98 (19) .8
Stenosis 237 (29) 93 (32) 144 (28) .3
Mixed regurgitation and stenosis 415 (51) 139 (47) 276 (53) .09
Aortic valve
Etiology
Degenerative 208 (26) 106 (36) 102 (20) .0001
Rheumatic 598 (73) 183 (62) 415 (80) .0001
Pathophysiology¶
Regurgitation 116 (14) 30 (10) 86 (16) .01
Stenosis 219 (27) 87 (29) 132 (25) .2
Regurgitation and stenosis 474 (58) 177 (60) 297 (57) .5
*2 test except as noted.
†Information incomplete in 3 patients.
‡Fisher’s exact test.
§Information incomplete in 5 patients.
Information incomplete in 7 patients.
¶Information incomplete in 4 patients.
Gillinov et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 6 1375
A
CD
There were 287 deaths after hospital discharge. After a
double valve replacement, the survival rate was 93%, 86%,
72%, 52%, and 34% at 30 days, 1, 5, 10, and 15 years,
respectively, after operation; after aortic valve replacement
and mitral valve repair, the survival rate was 95%, 89%,
79%, 63%, and 46% at these same time intervals (P  .01,
Figure 1, A). The instantaneous risk of death was highest
immediately after operation and fell to its lowest level at 1
year, rising slowly thereafter. However, this late phase of
hazard was consistently higher after mitral valve replace-
ment than repair (Figure 1, B).
Risk factors for death in the early phase of hazard in-
cluded more advanced New York Heart Association
(NYHA) functional class, nonrheumatic cause of valve dis-
ease, left main coronary disease, and use of a bovine peri-
cardial strip at annuloplasty for mitral valve repair (Table
5). In this early hazard phase, the difference between mitral
valve replacement versus repair could be due to chance (P
 .3, see Table 4 footnote). Risk factors for death in the late
phase of hazard included older age at operation, higher New
York Heart Association functional class, left ventricular
dysfunction, coronary artery disease, and preoperative atrial
fibrillation. In this late hazard phase, mitral valve replace-
ment increased risk (P  .03) modestly (hazard ratio 46%
higher than repair).
Survival Advantage of Mitral Valve Repair: Who
Benefits Most?
All groups of patients were predicted to have better 16-year
survival rates after mitral valve repair than replacement. The
survival benefit of repair was evident for patients with both
rheumatic and nonrheumatic mitral valve disease (Figure 2);
however, patients with rheumatic disease had a greater
predicted survival benefit than did patients with nonrheu-
matic disease (Figure 3). Other patient characteristics did
not influence the beneficial impact of mitral valve repair.
For example, although advanced age was a risk factor for
late death, the survival benefit of mitral valve repair was
evident in elderly patients (Figure 4).
Durability of Mitral Valve Repair
One hundred nineteen patients had late reoperation for
valvar dysfunction. Of these, 34 initially had mitral valve
repair and 85 mitral valve replacement (bioprostheses in 73
and mechanical prostheses in 12). Freedom from mitral
valve replacement after initial mitral valve repair differed
according to the underlying cause of the mitral valve dis-
ease. When the mitral valve disease was rheumatic, freedom
from mitral valve replacement was 99.3%, 97%, 89%, and
75% at 1, 5, 10, and 15 years, respectively, after operation.
In contrast, freedom from mitral valve replacement in non-
rheumatic disease was 98%, 91%, 88%, and 86% at these
same time intervals (Figure 5, A). This difference was
reflected in the different shape of the hazard functions
(Figure 5, B). For neither cause were we able to identify risk
factors for mitral valve replacement after initial mitral valve
repair. The most common reason for failed mitral valve
repair was progression of rheumatic disease. Figure 6 de-
picts freedom from mitral valve reoperation after mitral
valve repair or mitral valve replacement. As expected, those
patients receiving two mechanical valves had the highest
freedom from reoperation.
Discussion
Mitral Valve Replacement Versus Repair: Propensity
Analysis
Although not all mitral valves are repairable, most nonrheu-
matic valves and a substantial proportion of rheumatic
valves are amenable to repair. Therefore, in many cases, the
surgeon has a choice to make in treating the mitral valve in
patients with double valve disease.
During the last two decades, we have taken an aggressive
approach to mitral valve repair. In spite of this, most pa-
tients with combined aortic and mitral valve disease have
been managed with double valve replacement. This analysis
identified certain characteristics associated with use of mi-
tral valve repair rather than valve replacement. Patients
TABLE 4. Factors related to mitral valve replacement
rather than repair
Factor
Logistic coefficient
 SD
P
value
Patient
Preoperative atrial fibrillation* 0.62 0.23 .0006
Valve pathophysiology
Functional mitral valve regurgitation
with dilated anulus†
2.45 0.34 .0001
Calcified mitral leaflets 0.91 0.193 .0001
Mitral valve regurgitation (pure or
mixed lesion)
2.64 0.38 .0001
Mixed mitral regurgitation and
stenosis†
1.33 0.31 .0001
Severity of mitral stenosis‡ 0.26 0.08 .0009
Severe mitral stenosis 0.75 0.36 .04
Operative
Use of mechanical aortic prosthesis 0.87 0.23 .0002
and preoperative atrial
fibrillation*
0.91 0.39 .02
Experience
Earlier date of operation 0.053 0.0140 .0002
Intercept 1.21
C-statistic 0.81
*That is, patients with preoperative atrial fibrillation as a group were more
likely to have their mitral valve replaced rather than repaired, as were
those receiving a mechanical prosthesis in the aortic position. However, in
patients with atrial fibrillation, a mechanical aortic prosthesis did not
further augment the probability of replacement versus repair.
†Negative coefficient indicates higher likelihood of repair than replace-
ment.
‡Ordinal variable graded 0 to 6.
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requiring warfarin therapy for atrial fibrillation or a mechan-
ical aortic prosthesis usually received a mechanical mitral
prosthesis. Patients with severe mitral valve stenosis and
mitral valve leaflet calcification were more likely to undergo
mitral valve replacement rather than mitral commissurot-
omy. In contrast, patients with purely functional mitral
Figure 1. Time-related death after double valve surgery. A, Survival. Each symbol represents a death, positioned
according to the Kaplan-Meier estimator. Open squares represent patients undergoing aortic valve replacement
and mitral valve repair, and open circles represent patients undergoing double valve replacement. Vertical bars
are asymmetric confidence limits for these estimates. Superimposed are parametric survival estimates and their
confidence limits (solid line and dashed line, respectively). Numbers in parentheses represent patients traced
beyond the indicated interval. B, Instantaneous risk (hazard function) of death. Solid line (point estimates) and
coarse dashed lines (confidence limits) represent patients undergoing double valve replacement (replace), and
solid line enclosed within fine dashed lines represents patients undergoing aortic valve replacement and mitral
valve repair (repair).
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valve regurgitation were most frequently treated by mitral
valve repair, usually consisting of an annuloplasty alone.
This tendency to favor mitral valve replacement in cer-
tain groups of patients seemed logical. Patients requiring
warfarin for other reasons might be expected to derive the
greatest benefit from the excellent durability of a mechan-
ical mitral valve prosthesis. Repair of calcified mitral valves
presents a technical challenge with uncertain results, and
patients with such valves can be treated expeditiously and
reliably by mitral valve replacement. However, the long-
term outcome data do not support these practices. None of
the factors identified in the propensity analysis results in
improved survival for patients having mitral valve replace-
ment. Stated more explicitly, mitral valve replacement is
associated with decreased long-term survival in all patients
with double valve disease.
Survival Advantage of Mitral Valve Repair
The principal finding of this study is that mitral valve repair
improves late survival in patients with double valve disease.
This survival benefit extends to all patients, including the
elderly, those with coronary artery disease, those with de-
pressed left ventricular function, and those with rheumatic
and nonrheumatic mitral valve disease.
Mitral valve repair in patients with single valve disease
has been studied extensively.9-11,14,15 Since the introduction
of standardized techniques for mitral valve reconstruction
by Carpentier,24 Duran and Ubago,25 and others, mitral
valve repair has become the surgical treatment of choice for
mitral valve dysfunction. Numerous retrospective studies of
patients with single valve disease have demonstrated im-
portant benefits of mitral valve repair over mitral valve
replacement.9-11,14 Furthermore, it is likely that mitral valve
repair confers a survival advantage in patients with single
valve disease.9-11
Simultaneous operation on both valves is associated with
a hospital mortality rate of 5% to 15%.26-28 Most contem-
porary series document a 10-year survival rate of 50% to 70%
after double valve replacement; this is similar to late sur-
vival after isolated aortic or mitral valve replacement.1-4,7
TABLE 5. Risk factors for death
Risk factor
Hazard Phase
Early Late
Coefficient  SD P Coefficient  SD P
Demography
Older age — — 0.045 0.0066 .0001
Symptoms and clinical status
Higher NYHA class 0.13 0.032* .0001 0.046 0.0170† .007
and mitral valve replacement‡ 0.097 0.042 .02
Ventricular function
Moderate or severe left ventricular dysfunction — — 0.37 0.136 .006
Valve pathology and etiology
Non-rheumatic cause: aortic or mitral valve 0.69 0.24 .005 0.46 0.163 .005
Noncardiac comorbidity
Kidney disease — — 1.28 0.50 .009
Higher BUN§ 0.96 0.24 .0001 — —
and mitral valve repair 0.97 0.47 .04
Lower cholesterol level 2.0 0.88 .02 — —
Coronary artery disease
Left main trunk disease of any degree 0.92 0.29 .002 — —
Left circumflex system disease greater than 70% — — 0.65 0.20 .001
Operation
Bovine pericardial annuloplasty 1.03 0.42 .01 — —
Mitral valve replacement 4.32 1.60¶ .007 0.38 0.176 .03
Propensity adjustment
Probability of receiving mitral valve replacement 0.20 0.082 .01 0.025 0.056 .7
BUN, Blood urea nitrogen.
*Square transformation of augmented NYHA functional class where class V is emergency surgeries.
†Square transformation of nonaugmented NYHA functional class.
‡Association of NYHA to early mortality in mitral valve replacement group is different (P  .02) from that in the repair group, which is not significantly
different from zero (P  .2).
§Natural log transformation.
Inverse transform.
¶With only main effects in the early phase model, mitral valve replacement has minimal effect on early phase risk (0.20  0.33, P  .4), and the propensity
adjustment is small (0.13 0.073, P .08). With interaction terms in the model, these variables now represent intercepts, not risk factors. In the late hazard
phase, which does not include interaction terms, these terms are independent risk factors.
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There are little data examining the survival impact of
mitral valve repair in patients with double valve disease.
Kaul and coworkers7 performed aortic valve replacement
and mitral commissurotomy in 72 patients with rheumatic
disease. They had no operative deaths and a 9-year survival
rate in excess of 90%. Szentpetery8 demonstrated the fea-
sibility of aortic valve replacement and mitral valve repair
in 38 patients, most of whom had degenerative mitral valve
disease. With their small number of patients, they were
unable to demonstrate a survival advantage to mitral valve
repair. Mueller and colleagues29 found that patients having
mitral valve repair and aortic valve replacement demon-
strated a trend toward fewer valve-related complications
than did patients having double valve replacement; how-
ever, they, too, reported similar survival rates after mitral
valve repair and mitral valve replacement.
In the largest series of patients undergoing aortic valve
replacement and mitral valve repair, Grossi and colleagues5
Figure 2. Survival after double valve surgery stratified according to double valve replacement (replace) or aortic
valve replacement and mitral valve repair (repair). Depiction is as in Figure 1. A, Rheumatic disease; B,
nonrheumatic disease.
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analyzed 94 patients having this operative strategy. They were
unable to demonstrate a survival advantage to mitral valve
repair. Unfortunately, their study included a relatively small
group of patients with limited follow-up, and they did not
analyze all-cause death as an end point. In contrast, the current
analysis of more than 5000 patient-years of follow-up demon-
strates that mitral valve replacement is an independent predic-
tor of late death in patients with double valve disease.
Survival Advantage of Mitral Valve Repair: Who
Benefits Most?
Patients with double valve disease derive a survival benefit
from mitral valve repair. Examination of different sub-
groups of patients revealed that patients with rheumatic
mitral valve disease had a greater survival benefit with
repair than did patients with nonrheumatic disease. This is
accounted for in part by the finding that patients with
rheumatic disease have better late survival than those with
nonrheumatic disease, regardless of operative strategy. This
may be attributable in part to preserved left ventricular
function in patients with rheumatic mitral valve stenosis.
Although the prevalence of rheumatic heart disease is de-
clining in developed countries, most patients with double
valve disease have rheumatic valves. From this study, we
recommend that rheumatic mitral valves be repaired when-
ever possible in patients with double valve disease.
Durability of Mitral Valve Repair
After repair of rheumatic mitral valves, 15-year freedom from
valve replacement was 75%; in contrast, 15-year freedom from
valve replacement was 86% after repair of nonrheumatic
valves. Rheumatic cause decreases the durability of mitral
valve repair. However, the durability of repaired rheumatic
mitral valves exceeds that of bioprostheses in the mitral posi-
tion. Most importantly, rheumatic valve repair confers a sur-
vival advantage in spite of somewhat limited 15-year durability.
In most series of patients with single valve disease, 40%
to 75% of rheumatic mitral valves can be repaired.24 Dura-
bility of mitral valve repair in the rheumatic population is
lower than that in patients with degenerative disease.14,24
After repair for rheumatic mitral valve regurgitation, 15-
year freedom from reoperation is 76%.24 After open mitral
valve commissurotomy for mitral valve stenosis, 10-year
freedom from reoperation is 80% to 90%.15,30-32 Factors
reducing the durability of mitral valve repair in rheumatic
disease include younger patient age, pure mitral valve re-
gurgitation, mixed mitral valve regurgitation and mitral
valve stenosis, and leaflet calcification.15,30-32 However, late
survival is excellent after repair of rheumatic mitral valves,
and most authorities favor repair in such patients when
feasible.30-32 Although late mitral valve reoperation for
failed repair may be challenging in patients with an aortic
prosthesis, current data support an initial strategy of mitral
valve repair in patients with rheumatic double valve disease
when repair is feasible.
Limitations
This is a nonrandomized clinical study. Using the propen-
sity score, we have attempted to adjust the multivariable
Figure 3. Cumulative distribution of difference in percentage survival at 16 years between double valve replace-
ment and aortic valve replacement and mitral valve repair, stratified according to rheumatic and nonrheumatic
disease (see Analysis of Benefit under Patients and Methods). Only 1.7% of patients were predicted not to benefit
from repair (negative portion of axis not shown).
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analyses of outcomes for nonrandom selection factors re-
lated to choice of valvar procedure. However, it can not
adjust for unmeasured variables. The decision to repair or
replace the mitral valve was made by the surgeon. Not all
mitral valves are amenable to repair, particularly those with
extensive leaflet calcification. However, none of the sur-
geons in retrospect were able to identify with certainty
which of these patients they would not consider eligible for
at least attempted repair. Changing at times across the span
of this study, opinions differed and evolved about eligi-
bility for repair. Thus, we have included in the study all
patients who underwent operation during the entire time
frame.
Serial echocardiographic follow-up assessment of mitral
valve function was unavailable in most patients undergoing
mitral valve repair. Therefore, the data did not allow iden-
tification of patients who had recurrent mitral valve dys-
function but did not undergo reoperation, precluding an
Figure 4. Survival after double valve surgery according to age at operation. Depiction is a nomogram from the
multivariable analysis (Table 5) in which patient characteristics were entered as follows: NYHA Class II, left
ventricular dysfunction less than grade 3, no important coronary disease, sinus rhythm, blood urea nitrogen 20
mg/dL, no kidney disease. A, Rheumatic disease; B, nonrheumatic disease.
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assessment of durability on the basis of both reoperation and
recurrent valve dysfunction.
The outcomes analyzed were death and mitral valve
reoperation. Occurrence of valve-related complications
(thromboembolism, endocarditis, anticoagulant-related
hemorrhage) have been well studied and reported but were
not central to the purposes of this study. We were unable to
analyze the impact of chordal preservation on results after
mitral valve replacement.
Clinical Inferences and Decision Making
Mitral valve repair is possible in many patients with double
valve disease. It improves late survival rates and is more
durable than a bioprosthesis. Consequently, when a mitral
Figure 5. Freedom from mitral valve replacement after aortic valve replacement and mitral valve repair. Patients
are stratified according to rheumatic or nonrheumatic disease. Depiction is as in Figure 1. A, Freedom; B, hazard
function.
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valve that is amenable to repair is encountered in a patient
with double valve disease, it should be repaired rather than
replaced to ensure the best long-term outcome.
We thank Drs Nicholas G. Smedira and Joseph F. Sabik for
inclusion of their patients in this study; Colleen Vahcic, Deborah
Gladish, and the other members of the thoracic and cardiovascular
research team for their efforts in assembling and verifying the
clinical data and performing the follow-up; John Hendricks and
Linda DiPaola for constructing the data set; and, Tess Knerik for
editorial assistance.
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Appendix 1. Variables included in multivariable analyses of risk factors for death
Demographic
Age (years)
Height (cm)
Weight (kg)
Body mass index
Body surface area (m2)
Sex
Symptoms and clinical status
Emergency surgery
NYHA class, both I-IV and augmented to class V for emergency operations
Cause of valve disease
Aortic valve: degenerative, rheumatic
Mitral valve: degenerative, ischemic, rheumatic, functional
Pathophysiology of valve disease
Aortic regurgitation and degree of regurgitation, aortic stenosis, and degree of stenosis
Mitral regurgitation and degree of regurgitation, mitral stenosis and degree of stenosis
Mitral valve desease: calcified annulus, dilated annulus, calcification on leaflets, prolapse of anterior leaflet, prolapse of posterior
leaflet, elongated chordae to anterior leaflet, elongated chordae to posterior leaflet, rupture of anterior chordae, rupture of
posterior chordae
All combinations of aortic and mitral valve stenosis, regurgitation, and mixed lesions
Cardiac comorbidity
Family history of coronary artery disease, preoperative atrial fibrillation, left ventricular dysfunction, coronary artery disease
(maximum stenosis in left main trunk, left anterior descending, circumflex, and right coronary trunk systems), extent of coronary
system disease (0-3)
Noncardiac Comorbidity
Blood urea nitrogen, creatinine, renal disease, cholesterol, bilirubin, treated diabetes, smoking, hypertension, chronic obstructive
pulmonary disease, peripheral vascular disease
Operation
Mitral valve replacement vs repair
Aortic prosthesis: bioprosthesis, mechanical
Mitral prosthesis: bioprosthesis, mechanical
Mitral repair: site of repair (annulus, commissures, posterior leaflet, anterior leaflet), annuloplasty (with or without ring, Carpentier-
Edwards, Cosgrove, bovine pericardial annuloplasty), commissurotomy, leaflet resection (partial or complete, sliding or not),
repair of posterior leaflet, chordal resection, chordal shortening or transfer
Concomitant procedures
Coronary artery bypass grafting, ITA grafting, single vs bilateral ITA grafting, tricuspid valve replacement or repair
Experience
Date of operation, expressed on a continuous scale as years from January 1, 1975
ITA, Internal thoracic artery.
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Discussion
Dr Cary W. Akins (Boston, Mass). I congratulate Dr Gillinov
for his excellent presentation of this complex analysis of mitral
valve repair versus replacement when performed in combination
with aortic valve replacement. Unfortunately, I did not have the
manuscript long enough to fully evaluate the complex statistical
methods, even if I could have understood them, so I will try to look
at some of the basic issues concerning the study.
All surgical groups, including our own, who have reported the
advantages of mitral valve reconstruction versus replacement in
single valve disease have the a priori notion that the conclusion of
this manuscript must be correct. My innate prejudice favoring
mitral valve repair makes me believe the conclusion, but I am not
sure that the study actually proves the fact.
The study is retrospective and not randomized. The two patient
groups are different in significant ways. Although many factors
were assessed to try to statistically determine why surgeons chose
one operation over another, there are important areas of missing
information about factors that have been used to calculate propen-
sities and results.
Appendix Figure 1. Trends across time in management of patients with double valve disease. In these graphs, each
closed circle represents yearly proportion; a solid line is continuous probability by univariable logistic regression.
A, Proportion of patients in whom mitral valve was replaced; B, proportion of patients coming to operation with
rheumatic mitral valve disease versus degenerative mitral valve disease.
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